A Phase 2 interventional study of MRA(Tocilizumab) in Rheumatoid Arthritis, sponsored by Chugai Pharmaceutical. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-08-09.
Sponsored by Chugai Pharmaceutical · Phase 2, Interventional, and Treatment
This is an open-label, extension, Phase II study to evaluate the long-term safety and efficacy of MRA in Patients with RA who were participated in Study MRA009JP.
3,554 studies on the registry are indexed under Arthritis; 317 are open to participants now.
This study's enrollment of 135 is above the median of 90 across 2,377 interventional studies indexed under Arthritis.
Browse Arthritis studies →Chugai Pharmaceutical is the lead sponsor of 63 studies on the registry; 7 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients who received any of the following treatments between the start of preceding study and the registration of this study.
Drug: MRA(Tocilizumab)
8mg/kg/4 weeks for 1 year
ACR 20% responder rate compared to the pre-treatment in the preceding study
Time frame: throughout study
Frequency and severity of adverse events and adverse drug reactions
Time frame: week0,week4,week8,week12,and LOBS
Time course of DAS28,compared to the pre-treatment in the preceding study
Time frame: week 0,week 4,week 8,week 12, LOBS
Time course of the ACR 20%, 50%, and 70% responder rates compared to the pre-treatment in the preceding study
Time frame: week 0,week 4,week 8,week 12, LOBS
ACR N AUC compared to the pre-treatment in the preceding study
Time frame: week 0,week 4,week 8,week 12, LOBS
Time course of the ACR core set variables compared to the pre-treatment in the preceding study
Time frame: week 0,week 4,week 8,week 12, LOBS
No study locations are listed for this record.
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chugai Pharmaceutical